The cDNAs for three human UDP-N-Acetylgalactosamine; Polypeptide N- Acetylgalactosaminyltransferases (GaINAc transferases) have recently been cloned and sequenced. Recombinant, functional forms of these GaINAc transferases have been expressed. A partial cDNA has been obtained for a putative fourth member of this class of enzymes. These enzymes, which catalyze the addition of N-acetylgalactosamine (GaINAc) by an O-glycosidic linkage to serine and threonine residues (the first step in mucin-type glycosylation) show distinct specificities for some substrates and common specificities for other substrates (albeit with distinct kinetics). One implication of this finding is that the differential expression of these enzymes by different cells and organs may lead to the glycosylation of different sites on protein that are O-glycosylated with GaINAc. The positions of attachment of O-linked GaINAc to several mucin and mucin-like cell adhesion molecules will be evaluated for each of the recombinant GaINAc transferases. The substrates to be used include tandem repeats from different mucins and from mucin-like proteins such as the p-selection ligand PSGL-1. The patterns of expression of the different GaINAc transferases T1, T2, and T3 will be determined for normal tissues and tumors derived from them. The contribution of structural features of selected peptide substrates will also be e valuated by CD, NMR, and Molecular Modeling. The model system to be used will be the in vitro glycosylation of eleven residue peptides by different recombinant GaINAc transferases. One peptide (AHGVTSAPDTR) was selected for these studies for several reasons. It is among the best of the substrate peptides we have tested, its relative kcat/Km values is among the best of all substrates tested and it is a very effective substrate with all three of the recombinant transferases. Our initial characterization of structural features of this peptide using both NMR analysis and molecular modeling showed the presence of relatively stable structures. The peptide contains one threonine residue that is glycosylated, and one that is not glycosylated. Thus, investigation of this peptide may give us insight into molecular parameters that determine whether or not residues can be glycosylated by the action of these enzymes. In addition, we will characterize the nature of disulfide bonds among cysteine residues that are conserved among all GaINAc transferases cloned to date, and we will perform site specific mutagenesis on selected cysteine residues that may play a role in the catalytic activity of these enzymes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA069234-04
Application #
2895435
Study Section
Pathobiochemistry Study Section (PBC)
Program Officer
Mohla, Suresh
Project Start
1996-08-01
Project End
2001-05-31
Budget Start
1999-06-01
Budget End
2000-05-31
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Nebraska Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Omaha
State
NE
Country
United States
Zip Code
68198
Kinarsky, Leo; Suryanarayanan, Ganesh; Prakash, Om et al. (2003) Conformational studies on the MUC1 tandem repeat glycopeptides: implication for the enzymatic O-glycosylation of the mucin protein core. Glycobiology 13:929-39
Kirnarsky, L; Prakash, O; Vogen, S M et al. (2000) Structural effects of O-glycosylation on a 15-residue peptide from the mucin (MUC1) core protein. Biochemistry 39:12076-82
Kohsaki, T; Nishimori, I; Nakayama, H et al. (2000) Expression of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase isozymes T1 and T2 in human colorectal cancer. J Gastroenterol 35:840-8
Nishimori, I; Kamakura, M; Fujikawa-Adachi, K et al. (1999) Cholecystokinin A and B receptor mRNA expression in human pancreas. Pancreas 19:109-13
Beum, P V; Singh, J; Burdick, M et al. (1999) Expression of core 2 beta-1,6-N-acetylglucosaminyltransferase in a human pancreatic cancer cell line results in altered expression of MUC1 tumor-associated epitopes. J Biol Chem 274:24641-8
Reid, C J; Burdick, M D; Hollingsworth, M A et al. (1999) CFTR expression does not influence glycosylation of an epitope-tagged MUC1 mucin in colon carcinoma cell lines. Glycobiology 9:389-98
Kirnarsky, L; Nomoto, M; Ikematsu, Y et al. (1998) Structural analysis of peptide substrates for mucin-type O-glycosylation. Biochemistry 37:12811-7
Sharma, P; Dudus, L; Nielsen, P A et al. (1998) MUC5B and MUC7 are differentially expressed in mucous and serous cells of submucosal glands in human bronchial airways. Am J Respir Cell Mol Biol 19:30-7
Burdick, M D; Harris, A; Reid, C J et al. (1997) Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines. J Biol Chem 272:24198-202
Tempero, R M; Hollingsworth, M A; Burdick, M D et al. (1997) Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin. J Immunol 158:1377-82

Showing the most recent 10 out of 11 publications